Search

526 Result(s)
Sort by

More Potential

More Potential

Boehringer Ingelheim steps up its commitment to sustainable development, building on its historical success in addressing unmet health needs and increasing its ambitions to tackle global health and societal challenges.
Growing with us

Growing with us

We recognize the benefits of learning and have created an environment where life-long learning and personal growth are encouraged for all employees.
Phase II trials for patients with bronchiectasis

Phase II trials for patients with bronchiectasis

Bronchiectasis is a chronically progressive pulmonary disease. Boehringer Ingelheim investigates a potential new treatment option in two Phase II trials.
GioTag Final Data

GioTag Final Data

Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
Dirk Stenkamp

Dirk Stenkamp

Dirk Stenkamp, Senior Vice President Research Site Germany, reflects on our culture of collaboration and passion for progress.
Schizophrenia in real life

Schizophrenia in real life

Discover the reality of life with schizophrenia through the stories of people who are breaking down the stigma of living with a serious mental illness.
The impact of A Life in a Day of a patient

The impact of A Life in a Day of a patient

A Life in a Day disease simulations are opening our eyes to the patient experience, exposing a surprising knowledge gap and driving change.
2021 ABCD Young Scientist Award feline health

2021 ABCD Young Scientist Award feline health

Young veterinary researchers Julia Klaus and Dr Yasmin Parr receive award for their work into feline SARS-CoV-2 infections and feline leukaemia virus.
Our Partners_ViraTherapeutics

Our Partners_ViraTherapeutics

Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
Matthias Muenks

Matthias Muenks

Matthias Muenks, Global Engineering Process and Data Manager, speaks about our innovation and culture.
SPEVIGO®

SPEVIGO®

SPEVIGO® (spesolimab) is a novel, humanized, selective antibody for the treatment of generalized pustular psoriasis (GPP) flares.
Spiriva®

Spiriva®

Maintenance treatment of patients with COPD (including chronic bronchitis and emphysema), maintenance treatment of associated dyspnoea and for prevention of exacerbations.
Spiriva® Respimat®

Spiriva® Respimat®

An add-on maintenance treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids.
Spiolto® Respimat®

Spiolto® Respimat®

Maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
Striverdi® Respimat®

Striverdi® Respimat®

Maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).